No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients

Eur J Clin Pharmacol. 2007 May;63(5):527-8. doi: 10.1007/s00228-007-0284-6. Epub 2007 Mar 8.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / pharmacokinetics*
  • Cytochrome P-450 CYP1A2
  • Debrisoquin / metabolism
  • Dose-Response Relationship, Drug
  • Genotype
  • Humans
  • Mental Disorders
  • Mesoridazine / blood*
  • Phenothiazines / blood*
  • Polymerase Chain Reaction
  • Polymorphism, Genetic
  • Polymorphism, Restriction Fragment Length
  • Smoking
  • Thioridazine / administration & dosage
  • Thioridazine / pharmacokinetics*

Substances

  • Antipsychotic Agents
  • Phenothiazines
  • Mesoridazine
  • sulforidazine
  • Cytochrome P-450 CYP1A2
  • Thioridazine
  • Debrisoquin